Jade Biosciences (JBIO) 2026 Bloom Burton & Co. Healthcare Investor Conference summary

Company overview and strategy

• Focused on developing best-in-class therapeutics for autoimmune diseases, leveraging three antibody-based products licensed from Paragon with expertise in high-affinity binding and half-life extension.

• Pipeline includes three programs: JADE101 (anti-APRIL for IgA nephropathy), JADE201 (BAFF receptor targeting for B-cell depletion), and a third undisclosed program.

• Emphasis on biologically validated targets with potential for differentiated efficacy and patient convenience through extended dosing intervals.

• Strong development team with experience from Chinook Therapeutics and robust financial position, ending last year with $336 million to fund operations through 2028.

Lead program: JADE101 for IgA nephropathy

• JADE101 is an ultra-potent anti-APRIL antibody with half-life extension, aiming for best-in-class efficacy and dosing no more frequent than every eight weeks.

• Phase I healthy volunteer data expected this quarter, with phase II planned to start mid-year and patient data anticipated in 2027.

• IgA nephropathy represents a large and growing commercial opportunity, with recent approvals expanding the treatable population and pricing at $390,000/year.

• Selective anti-APRILs are expected to become the dominant class, with JADE101 positioned for superior potency, longer dosing intervals, and efficient registration pathway.

• KDIGO guidelines now recommend aggressive proteinuria reduction and treating IgA nephropathy as an autoimmune disease, supporting frontline use of anti-APRIL therapies.

Competitive landscape and differentiation

• Sibeprenlimab (Otsuka) and dual APRIL/BAFF agents have shown strong efficacy, but JADE101 aims to surpass them with higher potency and longer half-life.

• Preclinical data show JADE101 is 750-fold more potent than sibeprenlimab and has a four-fold longer half-life, targeting 55% IgA reduction in healthy volunteers.

• Efficient registration is possible due to biomarker-driven endpoints and a clear translational framework comparing JADE101 to competitors.